Translate Bio

$13.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.61 (-4.26%) Today
+$0.13 (+0.95%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Translate Bio and other stocks, options, and ETFs commission-free!

About TBIO

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Read More Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. The listed name for TBIO is Translate Bio, Inc. Common Stock.

Employees
93
Headquarters
Lexington, Massachusetts
Founded
2011
Market Cap
1.02B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.15M
High Today
$14.49
Low Today
$13.59
Open Price
$14.33
Volume
683.99K
52 Week High
$28.09
52 Week Low
$6.80

Collections

TBIO Earnings

-$0.74
-$0.49
-$0.25
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 5, After Hours

You May Also Like